The experimental coronavirus treatment remdesivir has failed in its first randomized clinical trial, inadvertently released results showed on Thursday, dampening expectations for the closely watched drug.
A draft summary went online briefly on the WHO Web site and was first reported by the Financial Times and health news Web site Stat, which posted a screenshot.
However, Gilead Sciences, the company behind the medicine, disputed how the now-deleted post had characterized the findings, saying that the data showed a “potential benefit.”
Photo: AFP
The Chinese trial involved 237 patients, with 158 on the drug and 79 in a control group, the summary said, adding that remdesivir was stopped early in 18 patients because of side effects.
The authors said that remdesivir was “not associated with a difference in time to clinical improvement” compared with the control.
After a month, 13.9 percent of the patients on remdesivir had died, compared with 12.8 percent of those in the control group. The difference is not statistically significant.
The WHO told the Financial Times that the draft is undergoing peer review and was published early in error.
“We believe the post included inappropriate characterizations of the study,” a Gilead spokesman told reporters, adding that it was terminated early due to low enrollment and was therefore not statistically meaningful.
“As such, the study results are inconclusive, though trends in the data suggest a potential benefit for remdesivir, particularly among patients treated early in disease,” the spokesman said.
The study does not represent the final word on the matter, and there are several large-scale trials in advanced stages that should soon provide a clearer picture.
Remdesivir, which is administered intravenously, was among the first drugs suggested as a treatment for the novel coronavirus and as such has great hopes riding on it.
Last week, Stat reported that it had shown significant efficacy at a Chicago hospital where patients who are part of one of the major trials are being treated.
The US National Institutes of Health also reported it that had proven effective in a small experiment on monkeys.
Remdesivir, which previously failed in trials against Ebola, belongs to a class of drugs that act on the virus directly — as opposed to controlling the abnormal and often lethal autoimmune response it causes. It mimics one of the four building blocks of RNA and DNA, and gets absorbed into the virus’ genome, which in turn stops the pathogen from replicating.
Anti-malarial drugs hydroxychloroquine and chloroquine have also been widely used on COVID-19 on a so-called “compassionate basis” pending results from large trials, with early studies decidedly mixed.
Other therapies that are being studied include collecting antibodies from COVID-19 survivors and injecting them in patients, or harvesting antibodies from genetically engineered mice that were deliberately infected.
Separately in France, new research shows that nicotine could protect people from contracting COVID-19.
The findings came after researchers at a top Paris hospital examined 343 COVID-19 patients, as well as 139 people with the illness who had milder symptoms.
They found that a low number of them smoked, compared with smoking rates of about 35 percent in France’s general population.
“Among these patients, only 5 percent were smokers,” said Zahir Amoura, the study’s coauthor and a professor of internal medicine.
The research echoed similar findings published in the New England Journal of Medicine last month suggesting that 12.6 percent of 1,000 people infected in China were smokers.
That was a much lower figure than the number of regular smokers in China’s general population, about 26 percent, WHO data showed.
The theory is that nicotine could adhere to cell receptors, therefore blocking the novel coronavirus from entering cells and spreading in the body, said neurobiologist Jean-Pierre Changeux from France’s Pasteur Institute, who also coauthored the study.
The researchers are awaiting approval from health authorities to carry out further clinical trials.
The researchers are looking into whether nicotine could help to prevent “cytokine storms,” a rapid overreaction of the immune system that scientists think could play a key role in fatal COVID-19 cases.
However, with further research needed, experts are not encouraging people to pick up smoking or use nicotine patches as a protective measure against the virus.
“We must not forget the harmful effects of nicotine,” French Director-General for Health Jerome Salomon said.
“Those who do not smoke should absolutely not use nicotine substitutes,” which cause side effects and addiction, he said.
FRUSTRATIONS: One in seven youths in China and Indonesia are unemployed, and many in the region are stuck in low-productivity jobs, the World Bank said Young people across Asia are struggling to find good jobs, with many stuck in low-productivity work that the World Bank said could strain social stability as frustrations fuel a global wave of youth-led protests. The bank highlighted a persistent gap between younger and more experienced workers across several Asian economies in a regional economic update released yesterday, noting that one in seven young people in China and Indonesia are unemployed. The share of people now vulnerable to falling into poverty is now larger than the middle class in most countries, it said. “The employment rate is generally high, but the young struggle to
ENERGY SHIFT: A report by Ember suggests it is possible for the world to wean off polluting sources of power, such as coal and gas, even as demand for electricity surges Worldwide solar and wind power generation has outpaced electricity demand this year, and for the first time on record, renewable energies combined generated more power than coal, a new analysis said. Global solar generation grew by a record 31 percent in the first half of the year, while wind generation grew 7.7 percent, according to the report by the energy think tank Ember, which was released after midnight yesterday. Solar and wind generation combined grew by more than 400 terawatt hours, which was more than the increase in overall global demand during the same period, it said. The findings suggest it is
IN THE AIR: With no compromise on the budget in sight, more air traffic controllers are calling in sick, which has led to an estimated 13,000 flight delays, the FAA said Concerns over flight delays and missed paychecks due to the US government shutdown escalated on Wednesday, as senators rejected yet another bid to end the standoff. Democrats voted for a sixth time to block a Republican stopgap funding measure to reopen government departments, keeping much of the federal workforce home or working without pay. With the shutdown in its eighth day, lines at airports were expected to grow amid increased absenteeism among security and safety staff at some of the country’s busiest hubs. Air traffic controllers — seen as “essential” public servants — are kept at work during government shutdowns, but higher numbers
Elvis Nghobo tried to get into four different professional schools in Cameroon, but could not make it. Frustrated, the 34-year-old turned to selling food at a market in Yaounde, the country’s seat of power. Nghobo blames his woes on what he calls a corrupt education system that favors children of the elite. As the central African country prepares for Sunday’s presidential election, he said he would not be heading out to vote. He called the results a foregone conclusion for 92-year-old Paul Biya, the world’s oldest president, who has ruled for Nghobo’s entire life. “He is already too old to govern, and it’s boring
RSS